American Capital Management Increases Stake in Novanta
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NOVT?
Source: Fool
- Share Increase: American Capital Management increased its stake in Novanta by 163,005 shares in Q4 2026, with an estimated trade value of $18.56 million, indicating confidence in the company's future growth prospects.
- Value Appreciation: As of February 17, 2026, the total shares held in Novanta reached 381,866, valued at $45.44 million, reflecting a $23.52 million increase from the previous quarter due to both share additions and price appreciation.
- Market Performance Analysis: Although Novanta's stock price has risen by 1% over the past year, it underperformed the S&P 500 by 10.4 percentage points, indicating relative weakness in the market.
- Industry Outlook: With signs of recovery in the medical and industrial OEM markets, Novanta's core business is expected to accelerate, despite a modest revenue growth of only 1.4% and a high P/E ratio of 99, leading investors to remain cautious about its valuation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NOVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NOVT
About NOVT
Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
American Capital Management Increases Stake in Novanta
- Share Increase: American Capital Management increased its stake in Novanta by 163,005 shares in Q4 2026, with an estimated trade value of $18.56 million, indicating confidence in the company's future growth prospects.
- Value Appreciation: As of February 17, 2026, the total shares held in Novanta reached 381,866, valued at $45.44 million, reflecting a $23.52 million increase from the previous quarter due to both share additions and price appreciation.
- Market Performance Analysis: Although Novanta's stock price has risen by 1% over the past year, it underperformed the S&P 500 by 10.4 percentage points, indicating relative weakness in the market.
- Industry Outlook: With signs of recovery in the medical and industrial OEM markets, Novanta's core business is expected to accelerate, despite a modest revenue growth of only 1.4% and a high P/E ratio of 99, leading investors to remain cautious about its valuation.
See More
American Capital Increases Stake in Novanta
- Share Increase: American Capital Management added 163,005 shares of Novanta in Q4 2026, with an estimated transaction value of $18.56 million, indicating confidence in the stock despite a mere 1% price increase over the past year.
- Value Appreciation: By quarter-end, the total value of American Capital's stake in Novanta reached $45.44 million, reflecting a $23.52 million increase from the previous quarter due to both trading activity and price appreciation.
- Asset Allocation Shift: Novanta now represents 2% of American Capital's reported AUM, indicating its growing significance in the investment portfolio, even though it remains outside the top five holdings.
- Market Performance Analysis: Despite Novanta's high P/E ratio of 99, significantly above the market average, and a modest revenue growth of 1.4%, signs of recovery in the medical and industrial OEM markets may support its future performance.
See More
ACK Asset Management Acquires New Position in Novanta
- New Position Disclosure: On February 13, 2026, ACK Asset Management disclosed a new position by acquiring 375,000 shares of Novanta, valued at approximately $44.62 million, marking a significant investment in the company.
- Asset Allocation Ratio: This acquisition represents 5.6% of ACK's 13F AUM, indicating a strong confidence in Novanta's future growth potential amidst a challenging market environment.
- Company Financial Overview: As of February 12, 2026, Novanta's share price stood at $139.29, reflecting a 5.7% decline over the past year and underperforming the S&P 500 by 18.63 percentage points, suggesting market caution regarding its growth prospects.
- Future Outlook: Novanta projects full-year 2025 revenue between $975 million and $979 million, with adjusted EBITDA expected to be between $222 million and $225 million, indicating potential growth opportunities as demand in medical and industrial sectors recovers.
See More
ACK Asset Management Acquires Novanta Shares
- New Shareholder Entry: ACK Asset Management acquired 375,000 shares of Novanta in Q4 2026, amounting to $44.62 million, marking a new investment that enhances its positioning in high-growth markets.
- Asset Allocation Shift: Novanta accounts for 5.6% of ACK's 13F AUM, indicating strategic importance in the industrial and infrastructure sectors, despite not being in the top five holdings.
- Strong Financial Performance: Novanta generated $247.8 million in Q3 revenue, up 1.4% year-over-year, with adjusted EBITDA rising from $57 million to $58.1 million, demonstrating competitiveness in the high-precision components market.
- Future Outlook: The company anticipates full-year 2025 revenue between $975 million and $979 million, with adjusted EBITDA of $222 million to $225 million, showcasing potential growth opportunities despite cash flow pressures from inventory and restructuring expenses.
See More
Analysis of Robotics ETF Investment Prospects
- Market Size Forecast: According to Precedence Research, the global robotics technology market is projected to reach $108.43 billion by 2026, with an anticipated growth of 283% to $416.26 billion by 2035, highlighting the long-term growth potential of the sector.
- BOTZ ETF Key Holdings: The top two holdings of the BOTZ ETF are Nvidia (10.89%) and Fanuc (9.13%), with Nvidia leveraging its advanced chips to significantly impact the AI sector, thereby enhancing investor confidence in robotics applications.
- ROBO ETF Investment Strategy: The primary holding of the ROBO ETF is Novanta (1.94%) along with Fanuc as its second-largest holding, focusing on broader diversification which reduces reliance on any single company, thus providing better risk management amid market volatility.
- Investor Selection Guide: The BOTZ ETF is suited for investors seeking concentrated exposure to major robotics and AI companies, while the ROBO ETF is better for those looking for broader diversification, reflecting the potential returns of different investment strategies within the robotics industry.
See More
Gossamer Bio (GOSS) Options Trading Volume Hits 36,131 Contracts, 73.1% of Average Daily Volume
- Active Options Trading: Gossamer Bio Inc (GOSS) recorded an options trading volume of 36,131 contracts today, equivalent to approximately 3.6 million shares, representing 73.1% of its average daily trading volume of 4.9 million shares over the past month, indicating strong market interest in its future performance.
- Put Options Highlighted: Notably, the $2 strike put option expiring on February 20, 2026, saw a significant volume of 12,338 contracts traded today, representing about 1.2 million underlying shares, reflecting investor expectations regarding potential downside risks for GOSS's stock price.
- Novanta Options Activity: Concurrently, Novanta Inc (NOVT) experienced an options trading volume of 3,468 contracts, equivalent to approximately 346,800 shares, which accounts for 72.7% of its average daily trading volume of 476,875 shares over the past month, showcasing ongoing market interest in its stock.
- Call Options Trading: Within NOVT's trading, the $140 strike call option expiring on February 20, 2026, stood out with a trading volume of 1,724 contracts today, representing around 172,400 underlying shares, indicating investor optimism regarding its future price potential.
See More
American Capital Management Increases Stake in Novanta
- Share Increase: American Capital Management increased its stake in Novanta by 163,005 shares in Q4 2026, with an estimated trade value of $18.56 million, indicating confidence in the company's future growth prospects.
- Value Appreciation: As of February 17, 2026, the total shares held in Novanta reached 381,866, valued at $45.44 million, reflecting a $23.52 million increase from the previous quarter due to both share additions and price appreciation.
- Market Performance Analysis: Although Novanta's stock price has risen by 1% over the past year, it underperformed the S&P 500 by 10.4 percentage points, indicating relative weakness in the market.
- Industry Outlook: With signs of recovery in the medical and industrial OEM markets, Novanta's core business is expected to accelerate, despite a modest revenue growth of only 1.4% and a high P/E ratio of 99, leading investors to remain cautious about its valuation.
See More
American Capital Increases Stake in Novanta
- Share Increase: American Capital Management added 163,005 shares of Novanta in Q4 2026, with an estimated transaction value of $18.56 million, indicating confidence in the stock despite a mere 1% price increase over the past year.
- Value Appreciation: By quarter-end, the total value of American Capital's stake in Novanta reached $45.44 million, reflecting a $23.52 million increase from the previous quarter due to both trading activity and price appreciation.
- Asset Allocation Shift: Novanta now represents 2% of American Capital's reported AUM, indicating its growing significance in the investment portfolio, even though it remains outside the top five holdings.
- Market Performance Analysis: Despite Novanta's high P/E ratio of 99, significantly above the market average, and a modest revenue growth of 1.4%, signs of recovery in the medical and industrial OEM markets may support its future performance.
See More
ACK Asset Management Acquires New Position in Novanta
- New Position Disclosure: On February 13, 2026, ACK Asset Management disclosed a new position by acquiring 375,000 shares of Novanta, valued at approximately $44.62 million, marking a significant investment in the company.
- Asset Allocation Ratio: This acquisition represents 5.6% of ACK's 13F AUM, indicating a strong confidence in Novanta's future growth potential amidst a challenging market environment.
- Company Financial Overview: As of February 12, 2026, Novanta's share price stood at $139.29, reflecting a 5.7% decline over the past year and underperforming the S&P 500 by 18.63 percentage points, suggesting market caution regarding its growth prospects.
- Future Outlook: Novanta projects full-year 2025 revenue between $975 million and $979 million, with adjusted EBITDA expected to be between $222 million and $225 million, indicating potential growth opportunities as demand in medical and industrial sectors recovers.
See More
ACK Asset Management Acquires Novanta Shares
- New Shareholder Entry: ACK Asset Management acquired 375,000 shares of Novanta in Q4 2026, amounting to $44.62 million, marking a new investment that enhances its positioning in high-growth markets.
- Asset Allocation Shift: Novanta accounts for 5.6% of ACK's 13F AUM, indicating strategic importance in the industrial and infrastructure sectors, despite not being in the top five holdings.
- Strong Financial Performance: Novanta generated $247.8 million in Q3 revenue, up 1.4% year-over-year, with adjusted EBITDA rising from $57 million to $58.1 million, demonstrating competitiveness in the high-precision components market.
- Future Outlook: The company anticipates full-year 2025 revenue between $975 million and $979 million, with adjusted EBITDA of $222 million to $225 million, showcasing potential growth opportunities despite cash flow pressures from inventory and restructuring expenses.
See More
Analysis of Robotics ETF Investment Prospects
- Market Size Forecast: According to Precedence Research, the global robotics technology market is projected to reach $108.43 billion by 2026, with an anticipated growth of 283% to $416.26 billion by 2035, highlighting the long-term growth potential of the sector.
- BOTZ ETF Key Holdings: The top two holdings of the BOTZ ETF are Nvidia (10.89%) and Fanuc (9.13%), with Nvidia leveraging its advanced chips to significantly impact the AI sector, thereby enhancing investor confidence in robotics applications.
- ROBO ETF Investment Strategy: The primary holding of the ROBO ETF is Novanta (1.94%) along with Fanuc as its second-largest holding, focusing on broader diversification which reduces reliance on any single company, thus providing better risk management amid market volatility.
- Investor Selection Guide: The BOTZ ETF is suited for investors seeking concentrated exposure to major robotics and AI companies, while the ROBO ETF is better for those looking for broader diversification, reflecting the potential returns of different investment strategies within the robotics industry.
See More
Gossamer Bio (GOSS) Options Trading Volume Hits 36,131 Contracts, 73.1% of Average Daily Volume
- Active Options Trading: Gossamer Bio Inc (GOSS) recorded an options trading volume of 36,131 contracts today, equivalent to approximately 3.6 million shares, representing 73.1% of its average daily trading volume of 4.9 million shares over the past month, indicating strong market interest in its future performance.
- Put Options Highlighted: Notably, the $2 strike put option expiring on February 20, 2026, saw a significant volume of 12,338 contracts traded today, representing about 1.2 million underlying shares, reflecting investor expectations regarding potential downside risks for GOSS's stock price.
- Novanta Options Activity: Concurrently, Novanta Inc (NOVT) experienced an options trading volume of 3,468 contracts, equivalent to approximately 346,800 shares, which accounts for 72.7% of its average daily trading volume of 476,875 shares over the past month, showcasing ongoing market interest in its stock.
- Call Options Trading: Within NOVT's trading, the $140 strike call option expiring on February 20, 2026, stood out with a trading volume of 1,724 contracts today, representing around 172,400 underlying shares, indicating investor optimism regarding its future price potential.
See More
